Search - tctmd.com

Displaying 141 - 160 of 325

Sort: Relevancy | Date

Presentation TCT 2019

Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science

Presenter: Ajay Kirtane

September 27, 2019

Presentation TCT 2019

The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease

Presenter: Marc Bonaca

September 26, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

Presentation TCT 2019

Novel Approaches in Diabetic Patients After PCI: Role of SGLT2 Inhibitors and Potent Antiplatelet Therapy (THEMIS)

Presenter: Marc Bonaca

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2019

Contemporary Antiplatelet/Anticoagulation Therapy Post-PCI

Presenter: Sorin Brener

September 25, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

Presentation TCT 2018

Choice and Duration of Antiplatelet and Anticoagulation Therapy After Venous Interventions (With Case Reviews)

Presenter: Brian G. DeRubertis, Mahmood K. Razavi, Anthony J. Comerota

September 24, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Three: Intravascular Imaging and Anticoagulation

Shelley Wood

September 24, 2018

Presentation TCT 2018

OAC-ALONE: A Randomized Trial of Oral Anticoagulation With vs Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation Beyond One Year After Coronary Stent Implantation

Presenter: Gregg W. Stone, Yukiko Nakano

September 24, 2018

Presentation TCT 2018

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

Presenter: Dominick J. Angiolillo, Neal S. Kleiman, Ajay J. Kirtane

September 24, 2018

Presentation TCT 2018

The Asian Anti-Platelet Therapy Paradox: Genetic Factors, Dosing, Bleeding, and Stent Thrombosis Risk

Presenter: Dominick J. Angiolillo, Elmir Omerovic, Duk-Woo Park

September 23, 2018

Presentation TCT 2018

Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

Presenter: Davide Capodanno, Giulio Stefanini, Robert A. Byrne

September 23, 2018

Presentation TCT 2018

US and ESC Guidelines and Consensus on Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing PCI

Presenter: Davide Capodanno, Giulio Stefanini, Dominick J. Angiolillo

September 23, 2018

Advertisement

Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science

The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Novel Approaches in Diabetic Patients After PCI: Role of SGLT2 Inhibitors and Potent Antiplatelet Therapy (THEMIS)

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Contemporary Antiplatelet/Anticoagulation Therapy Post-PCI

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Choice and Duration of Antiplatelet and Anticoagulation Therapy After Venous Interventions (With Case Reviews)

TCT 2018, Day Three: Intravascular Imaging and Anticoagulation

OAC-ALONE: A Randomized Trial of Oral Anticoagulation With vs Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation Beyond One Year After Coronary Stent Implantation

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

The Asian Anti-Platelet Therapy Paradox: Genetic Factors, Dosing, Bleeding, and Stent Thrombosis Risk

Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

US and ESC Guidelines and Consensus on Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content